Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 26 , ISSUE 8 ( August, 2022 ) > List of Articles


COVID-19 Vaccine-associated Thrombosis (Disseminated Intravascular Thrombosis) with Rare Cutaneous Involvement

Satyabrata Tripathy

Keywords : COVID-19, Disseminated intravascular thrombosis, Thrombosis, Vaccine

Citation Information : Tripathy S. COVID-19 Vaccine-associated Thrombosis (Disseminated Intravascular Thrombosis) with Rare Cutaneous Involvement. Indian J Crit Care Med 2022; 26 (8):963-965.

DOI: 10.5005/jp-journals-10071-24282

License: CC BY-NC 4.0

Published Online: 30-07-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Many COVID-19 vaccines have been used on the population all over the world. Not much is known about the vaccines and their adverse effects. A middle-aged lady got fever, body ache, and cutaneous lesions suggestive of disseminated intravascular thrombosis (DIC) almost immediately after COVID vaccination with very high D-dimer level in blood. She was successfully managed with timely initiation of treatment with steroids, anticoagulation, and antibiotics.

PDF Share
  1. McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021;85(1):46–55. DOI: 10.1016/j.jaad.2021.03.092.
  2. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARSCoV-2 vaccine. N Engl J Med 2020;384(5):403–416. DOI: 10.1056/NEJMoa2035389.
  3. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 396(10249):479–488. DOI: 10.1016/S0140-6736(20)31605-6.
  4. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21(2):181–192. DOI: 10.1016/S1473-3099(20)30843-4.
  5. Yang S, Li Y, Dai L, Wang J, He P, Li C, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis 2021;21(8):1107–1119. DOI: 10.1016/S1473-3099(21)00127-4.
  6. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397(10269): 99–111. DOI: 10.1016/S0140-6736(20)32661-1.
  7. Alobaid AM, Gosling CM, Khasawneh E, Khasawneh E, McKenna L, Williams B. Challenges faced by female healthcare professionals in the workforce: a scoping review. J Multidiscip Healthc 2020;13: 681–691. DOI: 10.2147/JMDH.S254922.
  8. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016;16(10):626–638. DOI: 10.1038/nri.2016.90.
  9. Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N Engl J Med 2021;384(13):1273–1277. DOI: 10.1056/NEJMc2102131.
  10. Ramos CL, Kelso JM. “COVID Arm”: very delayed large injection site reactions to mRNA COVID-19 vaccines. J Allergy Clin Immunol Pract 2021; 9(6):2480–2481. DOI: 10.1016/j.jaip.2021.03.055.
  11. Patel P, Walborn A, Rondina M, Fareed J, Hoppensteadt D. Markers of inflammation and infection in sepsis and disseminated intravascular coagulation. Clin Appl Thromb Hemost 2019;25:1076029619843338. DOI: 10.1177/1076029619843338.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.